Photo from wikipedia
IXEKIZUMAB is a humanized immunoglobulin G monoclonal antibody targeting the IL 17A, and labelled to treat moderate to severe plaque psoriasis. Benign skin reactions are a common adverse event when… Click to show full abstract
IXEKIZUMAB is a humanized immunoglobulin G monoclonal antibody targeting the IL 17A, and labelled to treat moderate to severe plaque psoriasis. Benign skin reactions are a common adverse event when using IXEKIZUMAB. In a meta-analysis of phase III studies, IXEKIZUMAB appears to have had the highest rate of skin reactions among all anti IL 17 and IL 12-23 agents (1), affecting approximately 25 to 30% of treated patients (2). A severe type III hypersensitivity resulting in serum sickness like reaction has been described (3). Our literature review showed no other case of severe allergy.
Journal Title: Journal of the European Academy of Dermatology and Venereology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!